Tags

Type your tag names separated by a space and hit enter

Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Eur J Neurol. 2010 Feb; 17(2):226-31.EJ

Abstract

BACKGROUND AND PURPOSE

Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of motor neuron degeneration in amyotrophic lateral sclerosis (ALS). We investigated the expression of MMPs and tissue inhibitors of matrix metalloproteinases (TIMPs) in serum and cerebrospinal fluid (CSF) correlating the results with age, disease duration and the clinical course.

METHODS

The material consisted of 30 ALS patients and 15 age-matched healthy controls. ELISA method to determine the expression of MT-MMP-1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in serum and CSF was used. MMP-2 and MMP-9 by zymography was also tested.

RESULTS

In serum MT-MMP-1, MMP-2, MMP-9 and TIMP-1 expression was increased, especially in mild ALS cases. TIMP-2 values were normal. In CSF MT-MMP-1, MMP-2 and TIMP-1 level was either increased or normal, that of MMP-9 was decreased. TIMP-2 did not change. No correlation of MMPs and TIMP-1 expression in serum and CSF and the age of the patients was found. A correlation was observed between MMPs and TIMPs and disease duration.

CONCLUSIONS

Increased level of MMPs and TIMP-1 of ALS patients may reflect the degeneration process of motor neurons and skeletal muscles and/or is associated with tissues remodeling. The low level of MMP-9 in CSF may result from impaired balance between MMP-9 and TIMP-1 and/or its increased intrathecal degradation and physical clearance. Although the role of changed MMPs/TIMPs level in the pathogenesis of ALS is not clear their analysis in serum may be used as prognostic factor and a potential marker for monitoring treatment effects.

Authors+Show Affiliations

Neuromuscular Unit, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland. dobosz@cmdik.pan.plNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19796283

Citation

Niebroj-Dobosz, I, et al. "Matrix Metalloproteinases and Their Tissue Inhibitors in Serum and Cerebrospinal Fluid of Patients With Amyotrophic Lateral Sclerosis." European Journal of Neurology, vol. 17, no. 2, 2010, pp. 226-31.
Niebroj-Dobosz I, Janik P, Sokołowska B, et al. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2010;17(2):226-31.
Niebroj-Dobosz, I., Janik, P., Sokołowska, B., & Kwiecinski, H. (2010). Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. European Journal of Neurology, 17(2), 226-31. https://doi.org/10.1111/j.1468-1331.2009.02775.x
Niebroj-Dobosz I, et al. Matrix Metalloproteinases and Their Tissue Inhibitors in Serum and Cerebrospinal Fluid of Patients With Amyotrophic Lateral Sclerosis. Eur J Neurol. 2010;17(2):226-31. PubMed PMID: 19796283.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. AU - Niebroj-Dobosz,I, AU - Janik,P, AU - Sokołowska,B, AU - Kwiecinski,H, Y1 - 2009/10/01/ PY - 2009/10/3/entrez PY - 2009/10/3/pubmed PY - 2010/8/18/medline SP - 226 EP - 31 JF - European journal of neurology JO - Eur J Neurol VL - 17 IS - 2 N2 - BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of motor neuron degeneration in amyotrophic lateral sclerosis (ALS). We investigated the expression of MMPs and tissue inhibitors of matrix metalloproteinases (TIMPs) in serum and cerebrospinal fluid (CSF) correlating the results with age, disease duration and the clinical course. METHODS: The material consisted of 30 ALS patients and 15 age-matched healthy controls. ELISA method to determine the expression of MT-MMP-1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in serum and CSF was used. MMP-2 and MMP-9 by zymography was also tested. RESULTS: In serum MT-MMP-1, MMP-2, MMP-9 and TIMP-1 expression was increased, especially in mild ALS cases. TIMP-2 values were normal. In CSF MT-MMP-1, MMP-2 and TIMP-1 level was either increased or normal, that of MMP-9 was decreased. TIMP-2 did not change. No correlation of MMPs and TIMP-1 expression in serum and CSF and the age of the patients was found. A correlation was observed between MMPs and TIMPs and disease duration. CONCLUSIONS: Increased level of MMPs and TIMP-1 of ALS patients may reflect the degeneration process of motor neurons and skeletal muscles and/or is associated with tissues remodeling. The low level of MMP-9 in CSF may result from impaired balance between MMP-9 and TIMP-1 and/or its increased intrathecal degradation and physical clearance. Although the role of changed MMPs/TIMPs level in the pathogenesis of ALS is not clear their analysis in serum may be used as prognostic factor and a potential marker for monitoring treatment effects. SN - 1468-1331 UR - https://www.unboundmedicine.com/medline/citation/19796283/Matrix_metalloproteinases_and_their_tissue_inhibitors_in_serum_and_cerebrospinal_fluid_of_patients_with_amyotrophic_lateral_sclerosis_ L2 - https://doi.org/10.1111/j.1468-1331.2009.02775.x DB - PRIME DP - Unbound Medicine ER -